Promacta Kit - (12 mg/packet and 25 mg/packet ; Oral Suspension)

Generic Name	Eltrombopag Olamine	Innovator	Novartis
Dosage	12 mg/packet and 25 mg/packet ; Oral Suspension	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	PROMACTA is a thrombopoietin receptor agonist indicated for the treatment of: 1) thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy 2) thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy 3)patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** ******	*** / *********	-**-	*** *********	********	*** ****** *******

Chronology Of Events